Inhibition of mitochondrial translation as a therapeutic strategy for human acute myeloid leukemia

Area of Science:

• * Molecular Biology
• * Oncology
• * Pharmacology

Background:

• * Identifying novel therapeutic agents for leukemia remains a critical challenge in cancer research.
• * Leukemia stem cells (LSCs) are crucial for disease initiation and relapse, making them attractive therapeutic targets.

Purpose of the Study:

• * To discover FDA-approved drugs with potential antileukemic activity.
• * To elucidate the mechanism of action for identified agents, focusing on LSCs.

Main Methods:

• * Conducted a chemical screen of FDA-approved agents against human leukemic cell lines.
• * Utilized genome-wide screening in yeast to determine the mechanism of drug-induced lethality.
• * Employed ShRNA-mediated knockdown of mitochondrial translation factors.
• * Assessed antileukemic activity in mouse models and compared cellular respiration in leukemic versus normal cells.

Main Results:

• * Identified tigecycline, an antimicrobial agent, as selectively toxic to leukemic cells.
• * Determined that tigecycline inhibits mitochondrial translation, leading to cell death.
• * Demonstrated tigecycline's efficacy against leukemia stem and progenitor cells in vitro and in vivo.
• * Observed enhanced mitochondrial biogenesis and oxygen consumption in acute myeloid leukemia (AML) cells compared to normal hematopoietic cells, correlating with tigecycline sensitivity.

Conclusions:

• * Tigecycline exhibits potent antileukemic activity by targeting mitochondrial translation, particularly in leukemia stem cells.
• * Mitochondrial function differences between leukemic and normal cells contribute to tigecycline's selective toxicity.
• * Tigecycline represents a promising candidate for novel leukemia therapies.